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The development of solid dosage forms that are both convenient for administration and 
allow precise drug dosing for pediatric patients is one of the great challenges in contemporary 
pharmaceutical technology. The presented study has utilized propranolol hydrochloride, as one 
of the most frequently prescribed drugs that require manipulation of the conventional dosage 
forms to be administered to children. Multiparticulate oral formulations, powder- and granule-
filled capsules, as well as mini tablets, were prepared and characterized in terms of their mass and 
content uniformity and compared to conventional marketed tablets split into halves and quarters. 
The obtained results have demonstrated the superiority of the multiparticulate formulations, in 
terms of their average mass and drug content uniformity. It has also been demonstrated that, due 
to improved flowability, granule-filled capsules are more conveniently compounded and provide 
higher content uniformity compared to powder-filled capsules. The presented compounding 
method could be easily employed in community pharmacy settings. Mini tablets with high and 
uniform content of propranolol hydrochloride have been successfully prepared, thereby 
presenting a viable strategy for efficient drug dose adjustment.  
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The development of solid oral dosage forms that are convenient for administration 
to pediatric patients is one of the current challenges, both from the perspective of 
pharmaceutical technology and pharmacotherapy. Compared to liquid products, which 
are predominantly formulated dosage forms for children, solid dosage forms may provide 
better stability, dosing accuracy, flexibility in administration, potential for modified drug 
release, affordable production, etc. (1-4). The development of pediatric solid dosage 
forms is recommended by the official guidelines as well (5,6). Solid oral dosage forms 
can be developed in a manner that allows ease of administration, favorable organoleptic 
properties, and accurate dosing with relatively simple formulations containing safe 
excipients in minimal amounts (7). 
There is a great therapeutical need for the development of cardiovascular medicines 
in dosage forms suitable for administration to children. A survey (8) reported that 
antiarrhythmics and antihypertensives (renin-angiotensin inhibitors and beta-blockers) 
are among the medicines most frequently used off-label or without a marketing 
authorization in pediatric patients. Propranolol hydrochloride, hereinafter referred to as 
PROP, is a non-selective beta-blocker used in the control of arrhythmia, hypertension, 
and pheochromocytoma in the pediatric population, usually at a dose of 0.25-0.5 mg/kg 
3-4 times daily, adjusted according to the clinical response. It is also used in migraine 
prophylaxis at a dose of 20 mg 2-3 times daily for children at the age of 12, and in doses 
of 80-160 mg daily (corresponding to the adult doses) for children over the age of 12. 
Moreover, PROP dose of 1 mg/kg 3-4 times daily is used for the treatment of congenital 
heart defect that involves four anatomical abnormalities referred to as Fallot’s tetralogy 
(9). 
Due to their wide therapeutic application, several PROP products are currently 
available on the European market (Table I) (9,10) in different dosage forms: sustained 
release capsules, (un)coated tablets and oral solutions. As listed in the Summary of 
Products’ characteristics (SmPC) (Table I) tablets and oral solutions can be administered 
to pediatric patients. However, PROP oral solutions are not available on the Serbian 
market. Furthermore, conventional solid oral dosage forms, such as tablets and capsules, 
may not be convenient for administration to children, due to inability or difficulties in 
swallowing (10). It is believed that children can safely swallow tablets and capsules from 
the age of six, but this is highly dependent on individual compliance and training, as well 
as on dosage form properties (size, shape and weight). There are no specific instructions 
in SmPCs regarding the administration of the marketed PROP products (Table I) to 
pediatric patients, especially in terms of adjustment of the required dose according to 
body weight.  
In order to adjust the pediatric dose and facilitate the administration of the medicine 
to a child, tablets can be manipulated in various ways. The most common practice 




concomitant side effects or changes in therapeutic effect (3). Another alternative is 
extemporaneous compounding of unit dose powders from commercially available tablets.  
Table I  Propranolol products for oral administration marketed in Europe (9-11) 
Tabela I  Preparati propranolola za oralnu primenu koji su registrovani u Evropi (9-11) 
 
Trade name, dosage(s) and 
manufacturer 
Dosage form and remarks from SmPCs relevant 
for administration of products to paediatric 
patients
Bedranol® 80 and 160 mg, 
Sandoz Ltd sustained release capsules 
 
(not suitable for use in children,  
according to SmPCs) 
Beta-Prograne® 160 mg 
Half Beta-Prograne® 80 mg 
Tillomed Laboratories Ltd 
Propranolol®,  
10, 40 and 80 mg,  
Accord Healthcare Ltd  
film-coated tablets 
(the score line is present but only to facilitate 
breaking for ease of swallowing and not to divide 
into equal doses) 
Propranolol 
10 and 40 mg, 
Aurobindo Pharma, Milpharm Ltd
film-coated tablets 
(can be divided into equal doses) 
Propranolol BP®, 
10, 40, 80 and 160 mg, 
Accord-UK Ltd 
film-coated tablets 
(division line is present but the manufacturer does 
not specify whether it allows easier swallowing 
and/or division into equal doses) 
Propranolol hydrochloride® 
5 mg/5 ml, 10 mg/5 ml, 40 mg/5 ml, 




(administered with graduated oral syringe or 
graduated cup; additional bottle adaptor) 
Propranolol Rosemont® 
5 mg/5 ml, 10 mg/5 ml, 40 mg/5 ml,  
50 mg/5 ml 
Rosemont Pharmaceuticals Ltd 
oral solution 
Hemangiol® 3.75 mg/ml 
Pierre Fabre Dermatologie 
oral solution 
(administered with graduated oral syringe) 
Propranolol® 40 mg, 
Galenika AD* 
uncoated tablets 
(can be divided in four equal doses) 





Multiparticulate systems, such as powders, granules, microparticles, pellets or mini 
tablets, provide the means for subdivision of the dose, as well as easier administration 
compared to the monolithic dosage forms (e.g. tablet). Due to their flexible nature, 
multiparticulate systems are expected to have wide applicability in the development of 
pediatric medicines (16). Multiparticulates can be packed in suitable, multidose 
containers (such as wide-mouthed glass jar), but in order to increase the dosing precision, 
it is more convenient to prepare single-dose preparations. For this purpose, subunits can 
be compressed into small tablets or packed into powder papers, sachets or hard capsules 
(17). In the latter case, hard capsules serve as a container i.e., they are not meant for 
swallowing in whole. Infants at the age of 6 months and toddlers can physiologically and 
anatomically swallow multiparticulates mixed with soft food or beverages, depending on 
the size, shape and hardness of the particles (7,18). Mini tablets (tablets with a diameter 
of up to 4 mm) have been proposed as a new modality of drug delivery for children at the 
age of 2 - 6 years (19). Mini tablets can be supplied in the form of paper or hard capsules, 
or they can be administered using a suitable dosing device or electronic dispenser if 
packed in multidose containers (7,18,20). Different options to administer 
multiparticulates to pediatric patients are depicted in Figure 1.  
 
Figure 1.  Administration methods for mini tablets and powder/granules within  
 pediatric dosage forms 
Slika 1.  Načini primene mini tableta i praškova/granula u sastavu farmaceutskih  
 oblika za pedijatrijsku populaciju 
 
The administration of multiparticulates with soft, semi-solid foods has been 
recommended for infants from the age of 6 months (5); however, in this case, particle size 




Mini tablets with sodium valproate (22), levetiracetam (23) and the enzymes amylase, 
lipase and protease (24) are available in the European Union (EU). Mini tablets with                   
150 mg of sodium valproate are intended for children from 6 months to 3 years, whereas 
mini tablets with 300 mg of sodium valproate are used in children over the age of 3. 
Unfortunately, none of these products is marketed in Serbia.  
The aim of this study was to assess the potential for the dose adjustment of PROP 
to the pediatric patients by using commercially available tablets and extemporaneously 
compounded multiparticulate oral formulations: powder-filled hard capsules, granule-
filled hard capsules, and mini tablets. 
Experimental part 
Materials 
Commercially available PROP tablets (Propranolol® 40 mg, Galenika AD, Serbia) 
were used to assess the accuracy of various tablet splitting techniques. In addition, 
commercially available tablets were used as a source of PROP, and together with directly 
compressible mannitol (Parteck® M 200, Merck, Germany), as a filler and sweetening 
agent, were used to extemporaneously compound powder-filled capsules. PROP, 
Parteck® M 200 and 5% aqueous solution of polyvinylpyrrolidone (PVP 40, Sigma 
Aldrich, Germany) were used to prepare granule-filled capsules. Mini tablets were 
prepared using PROP, Parteck® M 200 and magnesium stearate (Sigma-Aldrich, 
Germany) as a lubricant. The theoretical content of PROP in the prepared formulations 
(powder-filled capsules, granule-filled capsules and mini tablets) was 3 mg or 6 mg. 
Dilute hydrochloric acid (1% V/V; Sigma-Aldrich, Germany) and methanol (Merck, 
Germany), used as reagents, were of Ph. Eur. 10.0 quality. 
Methods 
1. Subdivision of scored tablets 
Propranolol® 40 mg scored tablets (Galenika AD, Serbia) were tested in terms of 
uniformity of mass of the subdivided parts, according to the procedure described in Ph. 
Eur. 10.0. Tablets (0478). In brief, 30 tablets were broken into halves or quarters, and one 
part (half or quarter) from each tablet was taken for the test. Each part was weighted 
individually, and the average mass and standard deviation (SD) were calculated. The 
tablets complied with the test if no more than one individual mass was outside the limits 
of 85-115% of the average mass. In contrast, the tablets failed to comply with the test if 
more than one individual mass was outside these limits or if one individual mass was 
outside the limits of 75-125% of the average mass. 
Since there is no standard procedure for tablet subdivision, we have tested five 
different splitting techniques: four techniques by hand (12) and using a commercially 





Figure 2.  The applied tablet splitting techniques: by hand 1-4, and using the tablet- 
 splitter 5; arrows represent the direction of the force applied during tablet  
 splitting  
Slika 2.  Primenjene tehnike deljenja tableta: ručno 1-4 i pomoću “sekača za  
 tablete” 5; strelice predstavljaju smer vršenja pritiska prilikom deljenja  
 tableta 
 
2. Preparation of powder- and granule-filled capsules 
Powder-filled hard capsules size 3 (capsule volume 0.3 ml) were prepared using 
semi-automatic capsules filling machine (Otima Aluminium®, Farmalabor, Italy), to 
comply with the procedure commonly used in local pharmacies. In order to prepare 40 
capsules needed for the study, each containing either 3 mg or 6 mg PROP, the number of 
required tablets was calculated (equal to 3 and 6 tablets, respectively). The tablets were 
pulverized in a mortar with a pestle, sieved through 180 μm mesh sieve, and then the 
powder was transferred to a graduated cylinder, followed by the subsequent addition of a 
filler (Parteck® M 200) to the required volume (12 ml). The powder from the graduated 
cylinder was transferred to a mortar, mixed well with a pestle, and used to fill hard 
capsules (kindly provided by Farmalabor, Serbia). 
Granule-filled hard capsules size 3 were prepared using PROP, Parteck® M 200 and 
5% PVP solution. Firstly, sufficient amounts of PROP obtained from the pulverized 
tablets and Parteck® M 200 were mixed in a mortar with pestle, followed by the gradual 
addition of the PVP solution (in a dropwise manner) until the required moisture content 
was achieved (inspected manually). The wet powder mixture was then sieved through a 
0.8 mm diameter mesh sieve. Upon drying under ambient conditions for 3 hours, the 




6.4 g of granules were needed, i.e. 160 mg of granules were needed to fill one capsule, 
according to the granules’ density and the capsule volume.  
3. Preparation of mini tablets  
The tablet mixture was prepared by mixing appropriate amounts of tablet 
ingredients in a mortar with a pestle for 10 minutes. PROP 3 mg mini tablets were 
prepared with PROP (23% w/w), Parteck® M 200 (75% w/w) and magnesium stearate 
(2% w/w), adjusting the average weight of the mini tablet to 13 mg. Similarly, PROP                   
6 mg mini tablets were prepared with PROP (37.5% w/w), Parteck® M 200 (60.5% w/w) 
and magnesium stearate (2% w/w), where the average mini tablet weight was 16 mg. Mini 
tablets were made by the direct compression method on a compaction analyzer Gamlen 
D-series (Gamlen Tableting, UK) using a punch and a die with 3 mm diameter. 
Compression was performed with a compression force of 1175 N.  
4. Flow properties of prepared powders and granules 
Flow properties of the prepared powders and granules were tested using both direct 
and indirect methods. The direct method is based on measuring the time required for the 
precise amount of powders/granules sample to pass through the orifice of the flow tester 
(Erweka flow meter GDT, Erweka GmbH, Germany). The test was performed in triplicate 
for each sample. The indirect method refers to the calculation of the Hausner ratio (HR) 
and Compressibility index (Carr index, CI), based on the measured bulk and tapped 
sample volumes, as according to the following equations (25). The bulk density was 
determined in a graduated 50 mL cylinder. 10 g of powder/granule sample was measured 
and poured into the cylinder. The bulk density was calculated as the ratio of 
powder/granule mass and read volume. The tapped density was determined by the 
mechanical tapping of the graduated cylinder containing 10 g sample of powder/granule 
using STAV 2003 tap density tester (J. Engelsmann, Germany). The number of taps was 
1250. The tapped density was calculated as the ratio of powder/granule mass and the final 
tapped volume. 
 
 𝐶𝐼  x 100     (1) 
 𝐻𝑅        (2)  
In accordance with the calculated CI and HR values, powder/granule flow was 









Table II  Flowability scale (25) 
Tabela II  Skala protočnosti (25) 
 
Carr index (%) Flow character Hausner ratio 
1 - 10 excellent 1.00 - 1.11 
11 - 15 good 1.12 - 1.18 
16 - 20 fair 1.19 - 1.25 
21 - 25 passable 1.26 - 1.34 
26 - 31 poor 1.35 - 1.45 
32 - 37 very poor 1.46 - 1.59 
> 38 very, very poor > 1.60 
 
5. Uniformity of mass of the prepared mini tablets and capsules 
The test was performed on 20 randomly selected mini tablets or capsules. Each 
tablet was accurately weighed using a BP201 D analytical balance (Sartorius AG, 
Germany). The average tablet mass and standard deviation (SD) from the average tablet 
mass were calculated for each sample. The uniformity of mass test for capsules was 
performed by measuring the difference between the mass of the intact capsule and the 
capsule shell.  
For both mini tablets and capsules, the compendial requirements were met if 
maximum two individual masses deviated by more than 10%, but no single individual 
mass deviated by more than 20% of the average mass (25). 
6. Content uniformity of PROP in the prepared mini tablets and capsules 
The test was performed by determining individual PROP content in 10 randomly 
taken mini tablets and capsules, and by calculating the average content. Each sample (i.e., 
crushed tablet or content of a capsule) was transferred to a 25 ml volumetric flask. Then, 
1 ml of dilute hydrochloric acid (1% V/V) was added and filled with methanol up to                   
2/3 of the flask volume and sonicated for 10 minutes on an ultrasonic bath (Bandelin 
Sonorex RK102H, Germany). After that, the volumetric flask was filled to the mark with 
methanol. PROP content was determined UV spectrophotometrically at the wavelength 
of maximum absorption (290 nm). The tablets and capsules comply with the test if not 
more than one individual content was outside the limits of 85% to 115% of the average 





Results and discussion 
According to the available data on the use of drugs for pediatric treatment in the 
local community, PROP is one of the ten most frequently prescribed drugs, where almost 
one-half of the total number of prescriptions were for cardiovascular drugs (26). The data 
also show that this drug is often prescribed in an off-label manner (in terms of the dose). 
Another issue concerning this drug is related to the unavailability of a suitable age-
appropriate dosage form and dose for pediatric patients. To exemplify this, the only 
available PROP product on the local market (uncoated tablets) is available in a single 
strength of 40 mg, although the SmPC states the tablets can be administered to pediatric 
patients in smaller, adjusted doses. For this purpose, it is recommended to split the tablet 
into up to four pieces (the tablets are scored with cross-lines to facilitate breaking, Figure 
3A).  
This procedure is related to two additional issues: firstly, the splitting of the tablet 
can only provide a single dose of 10-30 mg, which does not comply with the 
recommended dose adjustments based on a child’s body weight; secondly, it is 
questionable whether tablet splitting ensures uniform and appropriate dosing.  
In order to investigate the latter issue, we have tested the suitability of scored PROP 
tablets for splitting using five different splitting techniques. The results for the uniformity 
of mass of the subdivided parts are shown in Table III and Figure 4. 
The obtained results demonstrate that the pharmacopoeial requirements have been 
met solely for half-tablets obtained by techniques 4 and 5. However, the results for the 
splitting technique 5 should be taken with caution due to the visible loss of mass during 
tablet splitting (Figure 4B). Namely, Ph. Eur. 10.0 suggests that only one part from each 
tablet should be taken for the test (while rejecting the residual parts and “lost” fragments), 
and therefore compliance of the mass of the selected part with the required limits may 
represent false-positive results. Currently, there are no pharmacopoeial requirements for 
the maximum loss of mass upon tablet splitting, but this issue should be reconsidered in 
the future. Splitting techniques 1-3 resulted in higher variations between the tablet halves 
because the tablets often broke apart from the score line (Figure 4C). However, the most 
important finding is that none of the applied splitting techniques gave quarter-tablets of 
the appropriate mass (Table III). Regardless of the splitting technique, most of the tablets 
broke apart from the score lines, the obtained tablet quarters differed in mass, there were 
considerable mass losses, and some quarters even crumbled into multiple pieces (Figure 
3D). Although the product’s SmPC states that the tablets can be divided into four equal 
parts, the presented results clearly demonstrate that this statement is highly questionable. 
In addition, it was previously demonstrated (1) that active pharmaceutical ingredients 
may not be uniformly distributed within the dosage form, such as a tablet, which may 
potentially cause a non-uniform dose in the crushed tablet fragments. Therefore, 
additional options, besides the subdivision of tablets, should be considered to provide 
pediatric patients with the appropriate PROP dose. In this context, the crushing of tablets 
and concomitant compounding of a suitable dosage form i.e., multiparticulate system may 





Figure 3.  (A) The appearance of Propranolol® 40 mg scored tablets (Galenika AD,  
 Serbia); (B) Loss of mass after using a tablet-splitter; (C) Examples of  
 unequal half-tablets and (D) Examples of unequal quarter-tablets. 
Slika 3.  (A) Izgled Propranolol® 40 mg tableta (Galenika AD, Srbija); (B) Gubitak  
 mase prilikom deljenja tableta pomoću “sekača”; (C) Primeri nejednakih  
 polovina tableta i (D) Primeri nejednakih četvrtina tableta  
 
Table III  The results of the tablets subdivision test 
Tabela III  Rezultati ispitivanja deljivosti tableta 
 
Sample tested 
Average mass and 
standard deviation 
(g) 
Number of tablets outside the 
limits  Compliance 
with 



















HT  0.1020 ± 0.0134  7  -  - 
QT  0.0499 ± 0.0100  8  6  - 
2 
HT  0.1026 ± 0.0115  2  1  - 
QT  0.0534 ± 0.0100  9  4  - 
3 
HT  0.1050 ± 0.0221  16  6  - 
QT  0.0565 ± 0.0129  14  8  - 
4 
HT  0.1020 ± 0.0088  1  -  + 
QT  0.0528 ± 0.0056  3  -  - 
5 
HT  0.0950 ± 0.0078  -  -  + 
QT  0.0444 ± 0.0060  5  2  - 





Figure 4.  Uniformity of mass results of tablets split in (A) half or (B) quarter 
Slika 4.  Rezultati ispitivanja variranja mase tableta podeljenih na (A) polovine ili  






In addition, the compounding of other multiparticulate formulations should be 
evaluated. PROP granule-filled capsules and mini tablets prepared in this study are 
represented in Figure 5. Extemporaneous compounding of pediatric formulations can be 
quite useful, especially when the appropriate strength of a licensed medicine or adequate 
dosage form is not available, when the active substance or commercial preparation has 
unacceptable organoleptic properties (e.g., unpleasant taste or smell), or in cases of drug 
shortages (e.g., the medicine is not available from the supplier). However, this approach 
is associated with certain risks, and it is up to the pharmacist to prepare an age-appropriate 
medicine of appropriate quality, safety, stability, and efficacy.  
 
 
Figure 5.  The appearance of the compounded PROP multiparticulate oral  
 fomulations: granule-filled capsules and mini tablets 
Slika 5.  Izgled izrađenih višečestičnih formulacija propranolola za oralnu primenu:  
 kapsule punjene granulama i mini tablete 
 
Once the powder- and granule-filled capsules were prepared, they were tested for 
mass and content uniformity. In addition, both powder and granules’ flowability was 
analyzed. Results of the mass and content uniformity for PROP capsules (powder- and 
granule-filled) are represented in Table IV and Figure 6. The obtained results indicate that 
6 mg PROP granule-filled capsules met Ph. Eur. 10.0 requirements, since the individual 
mass of all 20 tested capsules fell within the allowed interval of ±10% of the average 
content mass. In the case of 6 mg PROP powder-filled capsules, the contents of 3 capsules 
varied by more than 10% of the average but were within ±20% of the average content 
mass. The obtained results for the content uniformity revealed that both in the case of 3 
mg and 6 mg PROP powder-filled capsules content of 2 capsules deviated from the ±15% 
tolerance limit. In the case of 3 mg PROP powder-filled capsules, one content varied more 
than ±25%. In that sense, 3 mg and 6 mg PROP powder-filled capsules failed to meet the 






Table IV  The results of mass variation and content uniformity test for powder–filled capsules, 
 granule–filled capsules and mini tablets 
Tabela IV  Rezultati ispitivanja variranja mase i ujednačenosti sadržaja za kapsule punjene 
 praškom, kapsule punjene granulama i mini tablete 
 
Sample tested 





the limits of the average 
mass
Number of tablets/capsules 
with PROP content outside 
the limits of the average 
PROP content 













 3 mg 
PROP 
0.2938 ± 0.0080 - - 2 1 
6 mg 
PROP 
















0.1955 ± 0.0053 - - - - 
6 mg 
PROP 










0.0129 ± 0.0004 - - 1 - 
6 mg 
PROP 
0.0156 ± 0.0004 - - 2 - 
 
On the other hand, PROP content in all of the 10 tested granule-filled capsules of 
both strengths was within the ±15% interval of the average content variation tolerated by 
Ph. Eur. 10. Therefore, in the case of granule-filled capsules, both 3 mg and 6 mg PROP 















Figure 6.  (A) Uniformity of mass results for PROP 3 mg and 6 mg powder-filled  
 capsules, granule-filled capsules, and mini tablets; (B) Results of the test for  
 uniformity of content for PROP 3 mg and 6 mg powder-filled capsules,  
 granule-filled capsules, and mini tablets 
Slika 6.  (A) Rezultati ispitivanja variranja mase za kapsule punjene praškom ili  
 granulama i mini tablete koje sadrže 3 mg ili 6 mg PROP; (B) Rezultati  
 određivanja ujednačenosti sadržaja za kapsule punjene praškom ili  




It can be assumed that differences in the powders and granules flowability may 
affect the uniformity of capsule filling. For that matter, the flow properties of samples 
were analyzed. The direct method for flowability determination indicated notable 
differences between powder and granules. Namely, the average flow rates were 4.85 g/s 
and 8.08 g/s for powder and granules, respectively. Almost double the amount of granules 
flows through the orifice of the flow tester at the same time compared to the powder, 
implying much better flow properties of granules. The results of the indirect flowability 
testing method confirm the assumption: the calculated CI and HR values for the powder 
(CI = 12.12% and HR = 1.14) characterized powder flow as “good”, whereas the granules 
flow properties were characterized as “excellent” (CI = 6.9% and HR = 1.07). Here, we 
need to point out that the use of Parteck®, an excipient with excellent flow properties (27) 
as a filler contributed to the overall flow characteristics of the prepared powder and 
granules. However, the granulation of powders, due to an increase in particle size, further 
improved their flow properties, and consequently, the uniformity of content of the 
prepared granules-filled capsules. It must be highlighted that improved flow properties 
are relevant not only for the time consumption for the overall capsule filling procedure, 
but also for the uniform flow that provides the uniform filling of capsules. Furthermore, 
the handling of granules during capsule-filling is much more convenient, compared to 
powders, in terms of potential dusting, spilling, etc. 
Regarding the properties of mini tablets, both 3 mg and 6 mg PROP mini tablets 
met the compendial requirements in terms of uniformity of mini tablets mass and PROP 
content (Table IV and Figure 6). It needs to be noted that due to the usage of directly 
compressible filler, it was possible to incorporate relatively high amounts of PROP in 
mini tablets (37.5% w/w for 6 mg PROP mini tablets). In that sense, PROP mini tablets 
provide the means for convenient and flexible adjustment of PROP doses. In practice, 
PROP mini tablets of different strengths could be combined to achieve the appropriate 
dosage. In terms of comparison of the variation of PROP content in different 
multiparticulate systems, the smallest variation was observed for granule-filled capsules, 
followed by mini tablets and then by the powder-filled capsules. Compared to the 
conventional tablets split into halves and quarters, multiparticulate oral formulations have 
been demonstrated to have significantly improved PROP content uniformity.  
Conclusion 
The study presented an investigation of the feasibility of appropriate PROP dose 
adjustment and uniform dosing, which is relevant for its administration to pediatric 
patients, by using different methods: the splitting of the conventional tablets and 
compounding of multiparticulate oral formulations– powder- and granule-filled capsules, 
as well as mini tablets. The obtained results are indicative of the superiority of 
multiparticulates for the test of uniformity of content for PROP. These findings support 
contemporary recommendations for the development of specific dosage forms for 
pediatric patients and are especially relevant due to the possibility of the application of 




study supports further development of mini tablets as a convenient dosage form for 
flexible dose adjustment. 
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Razvoj čvrstih farmaceutskih oblika lekova koji su prikladni za primenu kod pedijatrijske 
populacije pacijenata, ali koji istovremeno omogućavaju i precizno doziranje lekovite supstance, 
predstavlja jedan od vodećih izazova u farmaceutskoj tehnologiji. Prikazana studija koristi 
propranolol-hidrohlorid, kao jedan od najčešće primenjivanih lekova koji zahteva prilagođavanje 
farmaceutskih oblika za primenu kod dece. Višečestični farmaceutski oblici u vidu kapsula 
napunjenih praškom ili granulama, kao i mini tablete, su izrađene i ispitane u pogledu variranja 
mase i ujednačenosti sadržaja lekovite supstance. Dobijeni rezultati su upoređeni sa variranjem 
mase uzoraka koji se dobijaju deljenjem konvencionalnih registrovanih tableta na polovine i 
četvrtine. Dobijeni rezultati ukazuju na superiornost višečestičnih farmaceutskih oblika, zbog 
visokog stepena ujednačenosti mase i sadržaja lekovite supstance. Takođe je pokazano da se, zbog 
unapređene protočnosti, kapsule lakše pune granulama u odnosu na praškove, kao i da takvi 
farmaceutski oblici imaju veću ujednačenost mase i sadržaja lekovite supstance. Predstavljeni 
postupak izrade je jednostavan za izvođenje u uslovima apoteke. Mini tablete sa visokim udelom 
i ujednačenim sadržajem propranolol-hidrohlorida su uspešno izrađene, i predstavljaju značajnu 
strategiju koja može da omogući efikasno prilagođavanje doze lekovite supstance.  
 
Ključne reči:  propranolol, pedijatrijski farmaceutski oblici, višečestični sistemi,  
         mini tablete, ujednačenost sadržaja 
 
 
